Retatrutide
LY3437943
Retatrutide, also called LY3437943, is a single peptide agonist of GIP, GLP-1 and glucagon receptors. This triple-receptor profile separates it from tirzepatide and semaglutide.
Reviewed September 2026
- Residues
- 39. verified: 39 main-chain residues, including noncanonical residues. Lipid and gamma-glutamyl/ether linker are excluded from chain length but included in the molecular mass.
- Average mass
- 4,731 Da. verified: Reference form: Retatrutide/LY3437943: 39-residue main chain, including Aib and alpha-methyl-L-leucine, C-terminal amide and Lys17-linked C20 diacid/linker. Full modified reference molecule, not the unmodified registry sequence.; formula C221H342N46O68. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 39 |
|---|---|
| Average mass | 4,731 Da |
| pI | Not established |
| Aliases | LY3437943 |
|---|---|
| Research area | Metabolic |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Retatrutide/LY3437943: 39-residue main chain, including Aib and alpha-methyl-L-leucine, C-terminal amide and Lys17-linked C20 diacid/linker. Full modified reference molecule, not the unmodified registry sequence. Reference only, not a sold-lot measurement.
- Residues: 39 (verified). 39 main-chain residues, including noncanonical residues. Lipid and gamma-glutamyl/ether linker are excluded from chain length but included in the molecular mass. Residues source 1 Residues source 2 Residues source 3
- Average mass: 4,731 Da (verified). Reference form: Retatrutide/LY3437943: 39-residue main chain, including Aib and alpha-methyl-L-leucine, C-terminal amide and Lys17-linked C20 diacid/linker. Full modified reference molecule, not the unmodified registry sequence.; formula C221H342N46O68. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Retatrutide. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: a phase 2 trial. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Retatrutide
Identity and context
The three receptor targets describe pharmacology, not three mixed ingredients. A complete retatrutide structure must account for its chemical modifications. This entry deliberately omits a standard-residue-only sequence and calculated molecular mass that would imply an incomplete structure was sufficient.
Reference classification
Modified peptide. The linked catalogue product is Retatrutide. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Request lot-specific identity evidence that names LY3437943 or retatrutide and describes the full modified molecule. A generic incretin label is not enough to distinguish the three receptor profiles.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | The 2023 randomized phase 2 trial enrolled adults with obesity or overweight and a weight-related condition. It measured body-weight change and safety over 48 weeks. The investigators reported weight reduction, gastrointestinal adverse events and increases in heart rate. These findings must be read together rather than treating the efficacy outcome as a safety guarantee. | Source context |
| What cannot be inferred | The trial establishes results for the study preparation and enrolled population. It does not identify or test Aminos material. This reference is not a claim about current marketing authorization and does not turn a research catalogue item into a trial-equivalent medicine. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity: a phase 2 trialPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.